Predicting Success in the Biotech and Pharma Sectors Mark Schoenebaum of ISI Group earned two top spots on this year's All-America Research Team. Here he explains how he differentiates the good stocks from the bad. Related Articles For Members Only Biotech-Focused Hedge Funds Back Talawar’s Fast Moving SPAC Merger Stephen Taub For Members Only Beyond the Biggest Deals, Hedge Funds Are Backing Top IPO Performers Stephen Taub Creative Disruption: Private Markets in 2026 Sponsored by Franklin Templeton